Ben A C Dijkmans

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi [From splint to smart syringe: the changing perspective of rheumatology]
    Ben A C Dijkmans
    VU Medisch Centrum, afd Reumatologie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 155:A3470. 2011
  2. ncbi Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Michael T Nurmohamed
    Department of Rheumatology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Arthritis Res Ther 10:118. 2008
  3. ncbi Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus
    Irene E M Bultink
    Department of Rheumatology, VU University Medical Center, Postbox 7057, Amsterdam 1007 MB, The Netherlands
    Arthritis Res Ther 8:R183. 2006
  4. ncbi [The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]
    B A C Dijkmans
    VU Medisch Centrum, afd Reumatologie, Postbus 7057, 1007 MB Amsterdam
    Ned Tijdschr Geneeskd 149:688-93. 2005
  5. ncbi Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density
    M C Lodder
    Department of Rheumatology, Room 4A42, VU University Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 63:1576-80. 2004
  6. ncbi Reproducibility of bone mineral density measurement in daily practice
    M C Lodder
    Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 63:285-9. 2004
  7. ncbi Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs
    I E van der Horst-Bruinsma
    Department of Rheumatology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Clin Exp Rheumatol 20:S67-70. 2002
  8. ncbi Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis
    Melek Güler-Yüksel
    Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
    Arthritis Res Ther 12:R96. 2010
  9. ncbi Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
    Mirjam K de Vries
    VU University Medical Centre, Amsterdam, The Netherlands
    Arthritis Rheum 61:1484-90. 2009
  10. ncbi Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis
    Ruud Oerlemans
    Department of Rheumatology, Room 4A42, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Rheum Dis 66:1289-95. 2007

Detail Information

Publications74

  1. ncbi [From splint to smart syringe: the changing perspective of rheumatology]
    Ben A C Dijkmans
    VU Medisch Centrum, afd Reumatologie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 155:A3470. 2011
    ..Auto-antibodies are now detectable in the pre-clinical phase of RA; this means that in the future it will be possible to trace people with a raised risk of developing RA...
  2. ncbi Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Michael T Nurmohamed
    Department of Rheumatology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Arthritis Res Ther 10:118. 2008
    ..Biologics are, however, accompanied by less radiological deterioration...
  3. ncbi Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus
    Irene E M Bultink
    Department of Rheumatology, VU University Medical Center, Postbox 7057, Amsterdam 1007 MB, The Netherlands
    Arthritis Res Ther 8:R183. 2006
    ..In conclusion, SLE patients frequently suffer from infections, but deficiency of functional MBL does not confer additional risk...
  4. ncbi [The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]
    B A C Dijkmans
    VU Medisch Centrum, afd Reumatologie, Postbus 7057, 1007 MB Amsterdam
    Ned Tijdschr Geneeskd 149:688-93. 2005
    ....
  5. ncbi Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density
    M C Lodder
    Department of Rheumatology, Room 4A42, VU University Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 63:1576-80. 2004
    ..To examine variables associated with bone mineral density (BMD) in patients with rheumatoid arthritis (RA)...
  6. ncbi Reproducibility of bone mineral density measurement in daily practice
    M C Lodder
    Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 63:285-9. 2004
    ..Bone mineral density (BMD) measurements are frequently performed repeatedly for each patient. Subsequent BMD measurements allow reproducibility to be assessed...
  7. ncbi Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs
    I E van der Horst-Bruinsma
    Department of Rheumatology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Clin Exp Rheumatol 20:S67-70. 2002
    ..Altogether the number of therapeutic options for AS is limited and other drugs, such as leflunomide or thalidomide, should be explored further in placebo-controlled trials...
  8. ncbi Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis
    Melek Güler-Yüksel
    Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
    Arthritis Res Ther 12:R96. 2010
    ....
  9. ncbi Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
    Mirjam K de Vries
    VU University Medical Centre, Amsterdam, The Netherlands
    Arthritis Rheum 61:1484-90. 2009
    ....
  10. ncbi Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis
    Ruud Oerlemans
    Department of Rheumatology, Room 4A42, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Rheum Dis 66:1289-95. 2007
    ..The availability of drugs that could modulate GC resistance is therefore of potential clinical interest...
  11. ncbi Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial
    Naomi B Klarenbeek
    Department of Rheumatology, C 01 R, Leiden University Medical Center, P O Box 9600, Leiden 2300 RC, The Netherlands
    Ann Rheum Dis 69:1342-5. 2010
    ..To evaluate the effect of disease activity and antirheumatic treatment on blood pressure (BP) in patients with recent-onset rheumatoid arthritis (RA)...
  12. ncbi The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
    Naomi B Klarenbeek
    Department of Rheumatology, C 01 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Ann Rheum Dis 70:1039-46. 2011
    ..To compare clinical and radiological outcomes of four dynamic treatment strategies in recent-onset rheumatoid arthritis (RA) after 5 years follow-up...
  13. ncbi IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis
    Marijn Vis
    VU University Medical Center, Sanquin Research, and Jan van Breemen Institute, Amsterdam, The Netherlands
    J Rheumatol 35:425-8. 2008
    ....
  14. ncbi Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis
    Wouter H Bos
    Jan van Breemen Instituut, Sanquin Research, and VU University Medical Center, Department of Rheumatology, Amsterdam, The Netherlands
    J Rheumatol 35:1972-7. 2008
    ..To investigate the effect of anti-tumor necrosis factor (TNF) treatment on rheumatoid factor (IgM-RF) and anticitrullinated protein antibodies (ACPA) and its association with treatment response and acute-phase reactants...
  15. ncbi Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial
    Helena T J I de Leest
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    J Clin Gastroenterol 43:140-6. 2009
    ....
  16. ncbi Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide
    Joost W van der Heijden
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 60:669-77. 2009
    ..To determine whether multidrug-resistance efflux transporters are expressed on immune effector cells in synovial tissue from patients with rheumatoid arthritis (RA) and compromise the efficacy of methotrexate (MTX) and leflunomide (LEF)...
  17. ncbi Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study
    Mike J L Peters
    Correspondence to Dr Mike Peters, VU University Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 69:1281-5. 2010
    ..Data on the effects of tumour necrosis factor alpha(TNFalpha) blocking agents on circulating NT-proBNP levels in patients with active RA are lacking but may be informative...
  18. ncbi Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
    Diane Van der Woude
    Department of Rheumatology, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    Rheumatology (Oxford) 51:1120-8. 2012
    ..To compare the prevalence of and predictors for sustained drug-free remission in two cohorts of patients with recent-onset RA treated with DAS-driven therapy or non-DAS-driven therapy...
  19. ncbi Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study
    Lilian H D van Tuyl
    Department of Rheumatology, EMGO Institute, and the Department of Epidemiology and Biostatistics, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    J Rheumatol 36:1380-6. 2009
    ....
  20. ncbi Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
    Lilian H D van Tuyl
    VU University Medical Center, Department of Rheumatology, De Boelelaan 1117, Amsterdam, The Netherlands
    Ann Rheum Dis 69:1623-8. 2010
    ....
  21. ncbi The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia
    Lotte A van de Stadt
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratorium, Academic Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 70:128-33. 2011
    ..To determine the fine specificity of anti-citrullinated protein antibodies (ACPA) in the early phase of arthritis development, the ACPA repertoire in arthralgia patients and the association with arthritis development were studied...
  22. ncbi Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?
    Lilian H D van Tuyl
    Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1053 MB Amsterdam, The Netherlands
    Ann Rheum Dis 66:974-6. 2007
    ..In addition, 5 years of follow-up proved that COBRA therapy results in sustained reduction of the rate of radiological progression. Despite this evidence, Dutch rheumatologists seem reluctant to prescribe COBRA therapy...
  23. ncbi The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
    Anna Jamnitski
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Ann Rheum Dis 70:284-8. 2011
    ..The aim of this study was to test the hypothesis that the reason for non-response (caused by immunogenicity or not) to a first tumour necrosis factor (TNF) inhibitor defines whether a second TNF inhibitor will be effective...
  24. ncbi Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction
    Debby den Uyl
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 64:639-46. 2012
    ..To investigate the dose-related effects of glucocorticoid treatment on glucose tolerance, beta cell function, and insulin sensitivity in patients with early active rheumatoid arthritis (RA)...
  25. ncbi Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis
    Saskia Vosslamber
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 70:1153-9. 2011
    ..The goal of this study was to provide insight into pharmacological changes in peripheral blood that are associated with clinical response to rituximab...
  26. ncbi Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis
    Lilian H D van Tuyl
    VU University Medical Center, Department of Rheumatology, ZH 3A 56, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Rheum Dis 69:807-12. 2010
    ..This study evaluates survival, comorbidities and joint damage in the original COBRA trial cohort...
  27. ncbi Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial
    Izhar C van Eijk
    Jan van Breemen Research Institute Reade, Dr Jan van Breemenstraat 2, 1056 AB, Amsterdam, The Netherlands
    Rheumatology (Oxford) 51:686-94. 2012
    ..To compare the effects of aggressive tight control therapy and conventional care on radiographic progression and disease activity in patients with early mild inflammatory arthritis...
  28. ncbi Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice
    Danielle A Eekman
    Department of Rheumatology, VU University Medical Center, Amsterdam Netherlands
    BMC Musculoskelet Disord 12:167. 2011
    ..Monitoring osteoporosis therapy by measurement of bone turnover markers (BTMs) might detect non-compliance in an earlier stage of anti-osteoporosis treatment and improve persistence...
  29. ncbi Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study
    Yoony Y J Gent
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 64:62-6. 2012
    ....
  30. ncbi The BeSt story: on strategy trials in rheumatoid arthritis
    Naomi B Klarenbeek
    Department of Rheumatology, C 01 R, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The Netherlands
    Curr Opin Rheumatol 21:291-8. 2009
    ..To give an overview of recent strategy trials for the treatment of rheumatoid arthritis...
  31. ncbi Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus
    Irene E M Bultink
    Department of Rheumatology, VU University Medical Center, Slotervaart Hospital, and Jan van Breemen Institute, Amsterdam, The Netherlands
    Arthritis Rheum 52:2044-50. 2005
    ..To examine the prevalence of and risk factors for low bone mineral density (BMD) and vertebral fractures in patients with systemic lupus erythematosus (SLE)...
  32. ncbi Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis
    Marijn Vis
    Department of Rheumatology, VU University Medical Centre, Jan van Breemen Institute, Amsterdam, The Netherlands
    J Rheumatol 32:252-5. 2005
    ..The favorable effect of infliximab on cardiovascular comorbidity might not be mediated by effects on lipid metabolism, but longterm investigations are needed to confirm this...
  33. ncbi Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
    Joost W van der Heijden
    VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 60:12-21. 2009
    ....
  34. ncbi Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
    Geertje M Bartelds
    Jan van Breemen Research Institute, Amsterdam, The Netherlands
    JAMA 305:1460-8. 2011
    ..Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up...
  35. ncbi Pulmonary arterial hypertension in systemic sclerosis is associated with profound impairment of microvascular endothelium-dependent vasodilatation
    Herman M A Hofstee
    Department of Internal Medicine, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Rheumatol 39:100-5. 2012
    ..We investigated whether SSc patients with and without pulmonary arterial hypertension (PAH) show a graded impairment of microvascular function compared to healthy controls...
  36. ncbi Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
    Vokko P van Halm
    Department of Rheumatology, VU University Medical Center, Boelelaan 1117, Amsterdam, 1085 HV, The Netherlands
    Arthritis Res Ther 8:R151. 2006
    ..We hypothesize that DMARD use, in particular MTX use, results in powerful suppression of inflammation, thereby reducing the development of atherosclerosis and subsequently clinically overt CVD...
  37. ncbi [Rheumatoid arthritis: an equally strong risk factor for cardiovascular disease as diabetes mellitus]
    Mike J L Peters
    Vrije Universiteit Medisch Centrum, afd Reumatologie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A1469. 2010
    ..16 (95% CI: 1.28-3.63) and 2.04 (95% CI: 1.12-3.67) respectively. CONCLUSION: RA is associated with an increased risk of CVD and this risk is similar to that associated with DM2...
  38. ncbi Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab
    Marieke M J Herenius
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Occup Environ Med 52:618-21. 2010
    ..To assess the effect of 12-month treatment with adalimumab on work ability, quality of life, and fatigue in patients with active rheumatoid arthritis (RA)...
  39. ncbi Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study
    Hennie G Raterman
    Department of Rheumatology, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    J Rheumatol 38:247-51. 2011
    ..Anti-TNF treatment might limit thyroid dysfunction. Thus, changes in thyroid hormones were studied during TNF-blocking therapy in patients with RA...
  40. ncbi Serological bone markers and joint damage in early polyarthritis
    Louise M A Jansen
    Jan van Breemen Instituut and the Department of Rheumatology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Rheumatol 31:1491-6. 2004
    ..CONCLUSION: Increased serum levels of the bone turnover marker beta-CTx are associated with radiographic damage at baseline and radiographic progression after 2 years. However, beta-CTX is less predictive than markers already in use...
  41. ncbi Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study
    Cornelia F Allaart
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
    J Rheumatol Suppl 80:25-33. 2007
    ..To determine the efficacy, toxicity, utilities, and costs of 4 treatment strategies for patients with recent-onset rheumatoid arthritis (RA)...
  42. ncbi Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
    Sue Ellen Verbrugge
    Department of Rheumatology, VU Institute for Cancer and Immunology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    J Pharmacol Exp Ther 341:174-82. 2012
    ..These results indicate that the pharmacologic activity of these PIs may be hindered by drug resistance mechanisms involving PSMB5 mutations and PI extrusion via Pgp...
  43. ncbi Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors
    Markus M J Nielen
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Arthritis Rheum 50:380-6. 2004
    ..We conclude that IgM-RF and anti-CCP testing with appropriately high specificity may assist in the early detection of RA in high-risk populations...
  44. ncbi Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids
    Ruud Oerlemans
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 54:557-68. 2006
    ..These findings warrant further detailed investigations into the possible role of MRP-1 and other members of the superfamily of drug efflux pumps in diminishing the efficacy of DMARDs in rheumatoid arthritis treatment...
  45. ncbi Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies
    Mike J L Peters
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 69:1687-90. 2010
    ..Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent...
  46. ncbi Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
    Geertje M Bartelds
    Department of Rheumatology, Jan van Breemen Institute, Dr, Jan van Breemenstraat 2, 1056AB Amsterdam, The Netherlands
    Arthritis Res Ther 12:R221. 2010
    ..Therefore, we investigated whether a mismatch in IgG allotypes between adalimumab and IgG in adalimumab-treated patients is associated with the development of AAA...
  47. ncbi The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis
    Louise M A Jansen
    Department of Rheumatology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Rheumatol 30:1691-5. 2003
    ..The prognostic value of anti-CCP lies mainly in its ability to predict mild disease. This effect is accentuated in the subgroup of IgM-RF negative patients...
  48. ncbi Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
    Mike J L Peters
    VU Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 61:1571-9. 2009
    ..We prospectively assessed the incidence of CVD in patients with RA compared with patients with type 2 diabetes mellitus (DM) and the general population...
  49. ncbi Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis
    Markus M J Nielen
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Arthritis Rheum 50:2423-7. 2004
    ..The preclinical increase in CRP levels was observed both in donors with and in those without serologic abnormalities...
  50. ncbi Long-term follow-up of a high-intensity exercise program in patients with rheumatoid arthritis
    Zuzana de Jong
    Department of Rheumatology, C1 R, Leiden University Medical Center, Post Box 9600, 2300 RC, Leiden, The Netherlands
    Clin Rheumatol 28:663-71. 2009
    ..In contrast to those who did not continue exercising, they were able to preserve their gains in muscle strength without increased disease activity or progression of radiological damage...
  51. ncbi Reproducibility of performance measures of physical function based on the BASFI, in ankylosing spondylitis
    Salima F E van Weely
    Jan van Breemen Institute, Centre for Rheumatology and Rehabilitation, Dr Jan van Breemenstraat 2, 1056 AB, Amsterdam, The Netherlands
    Rheumatology (Oxford) 48:1254-60. 2009
    ..To establish the test-retest reproducibility of performance measures of physical function based on the Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaire in patients with AS...
  52. ncbi Bone formation rather than inflammation reflects Ankylosing Spondylitis activity on PET-CT: a pilot study
    Stefan T G Bruijnen
    Department of Rheumatology, VU University Medical Center, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
    Arthritis Res Ther 14:R71. 2012
    ..In a pilot setting, the potential of PET-CT in imaging AS activity was tested using different tracers, with Magnetic Resonance Imaging (MRI) and conventional radiographs as reference...
  53. ncbi The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
    Hennie G Raterman
    Department of Rheumatology, VU University Medical Center, De Boelelaan 1117, Amsterdam, 1081HV, The Netherlands
    Arthritis Res Ther 14:R95. 2012
    ..However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX...
  54. ncbi Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside
    Joost W van der Heijden
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    Nat Clin Pract Rheumatol 3:26-34. 2007
    ..More in-depth knowledge of the mechanisms behind these features could help facilitate a more efficient use of disease-modifying antirheumatic drugs...
  55. ncbi Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis
    Mike J L Peters
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    J Rheumatol 35:1495-9. 2008
    ..We investigated relations between oxLDL-ab, inflammation, subclinical atherosclerosis, and cardiovascular disease (CVD) in patients with RA...
  56. ncbi Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates
    Danielle A Eekman
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Musculoskelet Disord 10:86. 2009
    ..In this study we compared the effect on change in bone mineral density (BMD) of the spine and hip during long term treatment with pamidronate iv in comparison to OB...
  57. ncbi Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score
    Marion A J van Rossum
    Emma Children s Hospital AMC, Pediatric Rheumatology, Amsterdam, The Netherlands
    Arthritis Rheum 52:2865-72. 2005
    ..To evaluate the sensitivity to change of a newly developed radiologic assessment tool, the Dijkstra score, and to develop a numeric composite score and progressor classification scheme to apply in juvenile idiopathic arthritis (JIA) trials...
  58. ncbi Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis
    Mike J L Peters
    VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Rheumatol 37:161-6. 2010
    ..We investigated subclinical atherosclerosis and arterial stiffness in patients with AS compared with controls, and identified CV and AS related risk factors for atherosclerotic disease...
  59. ncbi Clinical approaches to early inflammatory arthritis
    Dirkjan van Schaardenburg
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
    Nat Rev Rheumatol 5:627-33. 2009
    ..The success of early treatment of inflammatory arthritis and the recognition of a measurable preclinical phase of RA offer hope that treating the disease before it becomes clinically active might be possible...
  60. ncbi The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis
    Alper M van Sijl
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    Semin Arthritis Rheum 41:393-400. 2011
    ..However, thus far, results have been inconsistent. Therefore, we investigated changes in lipid levels after TNF-alpha blocking therapy using meta-analysis of published data...
  61. ncbi Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study
    Mariette C Lodder
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 49:209-15. 2003
    ..To examine variables associated with bone mineral density (BMD) and vertebral deformities in women with rheumatoid arthritis (RA) from 3 northwest European countries...
  62. ncbi Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis
    J Christiaan van Denderen
    Jan van Breemen Instituut, Department of Rheumatology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Rheumatol 30:1558-60. 2003
    ..CONCLUSION: No significant improvement in any disease activity variable of active AS was observed during treatment with Salofalk except for the ESR. Many side effects were seen...
  63. ncbi Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis
    Lotte A van de Stadt
    Jan van Breemen Research Institute Reade, Sanquin Research, and Landsteiner Laboratorium, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 63:3226-33. 2011
    ..To examine how anti-citrullinated protein antibody (ACPA) epitope spreading takes place prior to the onset of clinical rheumatoid arthritis (RA), and to analyze the pattern of autoantigen reactivity at the beginning of the immune response...
  64. ncbi Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission
    Esmeralda T H Molenaar
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 50:36-42. 2004
    ..This suggests the need for markers that predict progression during periods of low disease activity and for drugs that prevent damage that is independent of disease activity...
  65. ncbi IL10 GGC haplotype is positively and HLA-DQA1*05-DQB1*02 is negatively associated with radiographic progression in undifferentiated arthritis
    Jennie Ursum
    VU University Medical Centre, Department of Rheumatology, 1007 MB Amsterdam, The Netherlands
    J Rheumatol 37:1431-8. 2010
    ..We investigated whether single-nucleotide polymorphisms (SNP) and haplotypes in immune response genes and HLA class II alleles are associated with radiographic progression in patients with early UA...
  66. ncbi Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation
    Mirjam K de Vries
    VU University Medical Centre, Rheumatology Department, room 4A 42, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 66:1252-4. 2007
    ..Correlation of serum trough infliximab levels and antibodies to infliximab (anti-infliximab) with clinical response in ankylosing spondylitis...
  67. ncbi Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis
    Lisa G M van Baarsen
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 62:694-704. 2010
    ..To identify molecular features associated with the development of rheumatoid arthritis (RA), to understand the pathophysiology of preclinical development of RA, and to assign predictive biomarkers...
  68. ncbi Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography
    Conny J van der Laken
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 58:3350-5. 2008
    ..We undertook this study to investigate whether rheumatoid synovitis can be visualized by PET using the tracer 11C-(R)-PK11195, which binds to peripheral benzodiazepine receptors (PBRs) on macrophages...
  69. ncbi High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life
    Irene E M Bultink
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
    J Rheumatol 35:1053-7. 2008
    ..To evaluate employment status in relation to organ damage, demographic factors, and health-related quality of life (HRQOL) in patients with systemic lupus erythematosus (SLE)...
  70. ncbi 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study
    Ernst H Elzinga
    Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
    J Nucl Med 52:77-80. 2011
    ..This study aimed to assess the association between changes in 18F-FDG joint uptake after 2 wk of infliximab treatment and clinical outcome...
  71. ncbi Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis
    Alejandro Martin-Trujillo
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 69:1239-42. 2010
    ..The aim of this study was to analyse whether the differential expression of IGF2, whose expression is normally restricted to one allele, is due to activation of the normally suppressed allele...
  72. ncbi Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells
    Michiel de Bruin
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Mol Pharmacol 66:1054-60. 2004
    ..However, this may also negatively affect capecitabine efficacy...
  73. ncbi Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis
    Gerrit Jansen
    Department of Rheumatology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Arthritis Rheum 50:2130-9. 2004
    ....
  74. ncbi Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial
    Yvonne P M Goekoop-Ruiterman
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
    Ann Intern Med 146:406-15. 2007
    ..In patients with early rheumatoid arthritis, initial combination therapies provide earlier clinical improvement and less progression of joint damage after 1 year compared with initial monotherapies (as demonstrated in the BeSt study)...